Last updated: 02/04/2020 18:50:17
META REGRESSION ANALYSIS TO INDIRECTLY COMPARE ELTROMBOPAG TO ROMIPLOSTIM FOR THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIA
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: META REGRESSION ANALYSIS TO INDIRECTLY COMPARE ELTROMBOPAG TO ROMIPLOSTIM FOR THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIA
Trial description: The purpose of this study is to conduct an indirect comparison on the safety and efficacy between eltrombopag and romiplostim in patients with chronic idiopathic thrombocytopenia (ITP).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Platelet Response
Timeframe: 6 weeks - 6 months
Secondary outcomes:
Discontinuation due to AEs
Timeframe: 6 weeks - 6 months
Interventions:
Drug: Eltrombopag
Drug: Romiplostim
Enrollment:
0
Observational study model:
Other
Primary completion date:
2013-26-08
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Thrombocytopaenia
Product
eltrombopag
Collaborators
Augmentium Pharma Consulting
Study date(s)
December 2008 to August 2013
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
- Studies must at least 10 patients enrolled into each treatment group
- Patients must have been adults 18 years of age or older
Inclusion and exclusion criteria
Inclusion criteria:
- Studies must at least 10 patients enrolled into each treatment group
- Patients must have been adults 18 years of age or older
- Diagnosed with chronic ITP that had relapsed after at least one treatment
- Randomized trials presented in abstract form at professional meetings were also eligible, provided that access to the full study reports was available
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2013-26-08
Actual study completion date
2013-26-08
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website